نتایج جستجو برای: melphalan

تعداد نتایج: 4419  

Journal: :journal of research in medical sciences 0
taleb azarm professor, hematology and oncology center, isfahan university of medical sciences, isfahan, iran mojtaba akbari epidemiologist, school of medicine, isfahan university of medical sciences, isfahan, iran arezoo azarm cellular and molecular biology, isfahan, iran hamid mohager resident, department of internal medicine, school of medicine, isfahan university of medical sciences, isfahan, iran

normal 0 false false false en-us x-none fa background : the aim of the study was to assess the effects of combination of bortezomib moderate dose and continuous oral low dose melphalan and thalidomide and dexamethasone (bmtd regimen) in elderly patients aged ≥ 65 years with relapsed multiple myeloma (mm). methods : twenty four patients with advanced mm were enrolled to receive eight 3-week trea...

2014
Nisha V. Shah D. G. Pham T. G. Murray C. Decatur E. Hernandez Nikesh N. Shah M. Cavalcante S. K. Houston

Purpose. To measure the chemotherapeutic effects of focal melphalan (intravitreal and subconjunctival) on tumor burden, hypoxia, and vasculature in LHBETATAG murine retinoblastoma model. Methods. LHBETATAG transgenic mice were treated with a single 1 mcg intravitreal injection of melphalan, 100 mcg subconjunctival injection, or semiweekly 10 mcg subconjunctival injections for 3 weeks. At 1 or 3...

Journal: :Nucleic Acids Research 2005
Peter H. Clingen Inusha U. De Silva Peter J. McHugh Farid J Ghadessy Michael J. Tilby David E. Thurston John A. Hartley

SJG-136, a pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimer, is a highly efficient interstrand crosslinking agent that reacts with guanine bases in a 5'-GATC-3' sequence in the DNA minor groove. SJG-136 crosslinks form rapidly and persist compared to those produced by conventional crosslinking agents such as nitrogen mustard, melphalan or cisplatin which bind in the DNA major groove. A panel of Ch...

Journal: :Blood 2008
Ping Zhou Julie Teruya-Feldstein Ping Lu Martin Fleisher Adam Olshen Raymond L Comenzo

In high doses with stem-cell transplantation, melphalan is an effective but toxic therapy for patients with systemic light-chain (AL-) amyloidosis, a protein deposition and monoclonal plasma cell disease. Melphalan can eliminate the indolent clonal plasma cells that cause the disease, an achievement called a complete response. Such a response is usually associated with extended survival, while ...

Journal: :Molecular cancer therapeutics 2007
Malin Wickström John Inge Johnsen Frida Ponthan Lova Segerström Baldur Sveinbjörnsson Magnus Lindskog Henrik Lövborg Kristina Viktorsson Rolf Lewensohn Per Kogner Rolf Larsson Joachim Gullbo

Neuroblastoma is the most common extracranial solid tumor of childhood. The activity of J1 (l-melphalanyl-p-l-fluorophenylalanine ethyl ester), an enzymatically activated melphalan prodrug, was evaluated in neuroblastoma models in vitro and in vivo. Seven neuroblastoma cell lines with various levels of drug resistance were screened for cytotoxicity of J1 alone or in combination with standard cy...

Journal: :European journal of cancer 1997
J van der Zee B B Kroon O E Nieweg S A van de Merwe H H Kampinga

The addition of hyperthermia (HT) to regional isolated perfusion (RIP) with Melphalan theoretically has two advantages. Firstly, heat can selectively kill cells in poorly vascularised areas that are usually not reached by the drug. Secondly, in vitro data have revealed that the effect of Melphalan is enhanced at temperatures 39-45 degrees C. However, for the simultaneous application of Melphala...

2007
Ping Zhou Julie Teruya-Feldstein Ping Lu Martin Fleisher Adam Olshen Raymond L Comenzo

In high doses with stem-cell transplantation, melphalan is an effective but toxic therapy for patients with systemic lightchain (AL-) amyloidosis, a protein deposition and monoclonal plasma cell disease. Melphalan can eliminate the indolent clonal plasma cells that cause the disease, an achievement called a complete response. Such a response is usually associated with extended survival, while n...

2017
Stefano Guadagni Giammaria Fiorentini Marco Clementi Giancarlo Palumbo Francesco Masedu Marcello Deraco Giovanni De Manzoni Alessandro Chiominto Marco Valenti Cristina Pellegrini

Approximately 25% of melanoma patients with locoregional metastases are nonresponsive to new molecular target therapy and immunotherapy. When metastases are located in the pelvis, melphalan hypoxic perfusion can be an optional treatment. Because methylation of MGMT promoter increases the efficacy of alkylating agents, studies on melanoma outcome of patients treated with melphalan regional chemo...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 1993
M G Bolton J Hilton K D Robertson R T Streeper O M Colvin D A Noe

The reaction kinetics of the hydrolysis, phosphatolysis, glutathionyl conjugation, and alpha-glutathione-S-transferase (GST)-catalyzed glutathione conjugation of [3H-ring]melphalan were investigated at pH 6.5 and 7.4. The distribution of products relative to the initial parent compound radioactivity over time was measured by HPLC and analyzed by nonlinear regression techniques using a system of...

2015
Ting Xiong Xiaoqiong Chen Heng Wei Hui Xiao

INTRODUCTION The aim of this study was to evaluate the potential biological activity of N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-(N,N-dimethylamino)acetamide hydrochloride (PJ34) on the genotoxicity induced by melphalan in human multiple myeloma cells. MATERIAL AND METHODS The inhibitory effects of the drugs on the growth of RPMI8226 cells were determined by Cell Counting Kit-8 (CCK-8) assay. ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید